Adalimumab biosimilar by Biocon for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval

Adalimumab biosimilar is under clinical development by Biocon and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris).

Medtech’s top executive moves in 2024

The new year ushered in a wave of changes in executive suites across the medtech landscape. Several medical device and diagnostics companies have named new

April 25, 2024

Social media algorithms are driving the GLP-1 drugs boom – Pharmaceutical Technology

GLP-1 RA drugs are prescribed as treatments for patients with type 2 diabetes, or obesity. Credit: UCG / Getty. A rapid growth in demand for

October 3, 2024

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update – Biotech Investments

Issuer: Immunic, Inc. / Key word(s): Annual Results 22.02.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc.

February 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.